Monthly Archives: April 2020

Abivax Postpones the Publication of the Yearly Universal Registration Document (‘URD’)

PARIS, FRANCE / ACCESSWIRE / April 29, 2020 / Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today postponed the release of its yearly "Universal Registration Document 2020 (URD)" due to technical reasons caused by the COVID-19 pandemic.

The Company is carrying out an in-depth analysis of potential risks, as well as newly emerging opportunities, considering the recent COVID-19 related developments. In order to be able to provide a complete Company update, the universal registration document will be released by the end of May at the latest in accordance with the exceptional regulatory guidelines relating to COVID-19.

About Abivax (www.abivax.com)

Abivax is mobilizing the body's natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

Contacts

Abivax
Finance
Didier Blondel
didier.blondel@abivax.com
+33 1 53 83 08 41
Abivax
Communications
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63
Investors
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254

Press Relations & Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22
Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 1 56 88 11 22
Public Relations USA
Rooney Partners LLC
Marion Janic
mjanic@rooneyco.com
+1 212 223 4017

DISCLAIMER

This press release contains forward-looking statements, forecasts and estimates with respect to certain of the Company's programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document de Référence). Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law.

This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

SOURCE: Abivax SA

ReleaseID: 587618

WORX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of SCWorx Corp. and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / April 29, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SCWorx Corp. ("SCWorx " or "the Company") (NASDAQ:WORX). Investors who purchased SCWorx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/worx.

The investigation concerns whether SCWorx and certain of its officers and/or directors have violated federal securities laws.

On April 13, 2020, SCWorx announced that it had receive a committed purchase order of two million COVID-19 rapid testing kits, "with provision for additional weekly orders of 2 million units for 23 weeks, valued at $35M per week." On this news, SCWorx's stock price increased by $9.77, closing at $12.02 per share on April 13, 2020. Then, on April 17, 2020, Hindenburg Research published a report questioning the validity of SCWorx's purported deal, which it characterized as "completely bogus." Among other issues, the Hindenburg Research report focused on the background of SCWorx's Chief Executive Officer Marc Schessel, questioned the credibility of the Company's supplier Promedical, and highlighted the relatively small size of the Company's client Rethink My Healthcare. On this news, SCWorx's stock price fell sharply over the following trading sessions. On April 22, 2020, the U.S. Securities and Exchange Commission halted trading of SCWorx's stock.

If you are aware of any facts relating to this investigation, or purchased SCWorx shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/worx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 587617

Pac Roots Completes Acquisition of Cannabis Act License Applicant and Related Phenome One Genetic Licensing Transaction, $1,650,000 Non-Brokered Private Placement, Set to Begin Trading Under Symbol “PACR”

VANCOUVER, BC / ACCESSWIRE / April 29, 2020 / Pac Roots Cannabis Corp. (formerly Mountain Lake Minerals Inc.) (CSE:MLK) (the "Company") is pleased to announce that, further to its press releases dated March 15, 2018, June 8, 2018, July 12, 2018, July 18, 2018, January 18, 2019, April 5, 2019, April 11, 2019, June 7, 2019, August 15, 2019, the Company has completed its previously announced acquisition of an application for a license under the Cannabis Act (Canada), indirectly through the acquisition of 1157630 B.C. Ltd.. (the "Acquisition") as well as the licensing arrangement with Phenome One Corp. ("Phenome"), a private held full service live genetic cannabis company. The Company has also changed its name from Mountain Lake Minerals Inc. to "Pac Roots Cannabis Corp.". The Company expects to commence trading on the Canadian Securities Exchange ("CSE") on May 4, 2020 under the symbol "PACR".

Acquisition

As previously announced, under the provisions of the Acquisition, the Company acquired all of the issued and outstanding securities of 1157630 B.C. Ltd. (the "Target") in consideration of the issuance of 40,000,000 common shares of the Company (the "Payment Shares"). The Target is now a wholly owned subsidiary of the Company. All of the Payment Shares are subject to escrow pursuant to the policies of the CSE and will be released from escrow based on the passage of time, such that 10% of the securities were released on closing and the balance will be released in six equal tranches of 15% every six months thereafter. An additional, 3,383,333 common shares were issued to a historical owner of the Target's wholly owned subsidiary, Go Green Medicinal Marijuana Ltd. ("Go Green"), which common shares are subject to resale restrictions expiring on August 29, 2020.

Go Green holds an application for a license under the Cannabis Act (Canada) which has successfully advanced through the review and security clearance stages of the license application process and expects to complete the pre-licensing and approval process following the submission of its security and video evidence package in Q2 2020, following which Go Green expects it would be issued its license. Go Green has a 12,000 square foot indoor growing facility in Lake Country, British Columbia. Go Green has nearly completed an expansion on the facility which will increase its size to 22,000 square feet.

Upon the completion of the closing of the Acquisition, the Company issued 200,000 common shares to Matthew McGill pursuant to a finder's fee agreement dated June 6, 2018 (the "Finder's Fee Agreement") entered into in association with the Acquisition. These shares are subject to a hold period under securities laws ending on August 29, 2020 and are also held in escrow on the same terms as the Payment Shares. Mr. McGill is a director of the Company and thus a related party to the Company. At the time the Finder's Fee Agreement was executed however, Mr. McGill was not associated with the Issuer and as a result the Finder's Fee Agreement and the issuance of the common shares thereunder does not constitute a ‘related party transaction' pursuant to Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions.

Phenome One License

The Company has entered into a genetic licensing royalty agreement dated April 8, 2019, as amended (the "Licensing Agreement") with Phenome. The Licensing Agreement provides the Company with full access to Phenome's entire library of cultivars as well as access to Phenome's farming intellectual property ("IP"). The Company will also be granted unlimited access to Norstar Nutrients' ("Norstar") proprietary nutrient IP and catalogue.

In consideration for the rights granted to the Company under the Licensing Agreement, the Company will pay an aggregate of $250,000 in cash and issue an aggregate of 10,000,000 common shares in the capital of the Company to Phenome over a 30-month period, of which 2,500,000 common shares were issued upon closing.

The Company will also make non-refundable, non-creditable royalty payments to Phenome equal to five percent (5%) of gross sales of products. The Company will acquire a 50% interest in all hybrid cultivars generated from the extensive selective breeding program at the Lake Country facility.

Private Placement

In connection with the closing of Acquisition and License, the Company completed a non-brokered private placement (the "Placement") generating aggregate gross proceeds of $1,650,000 through the issuance of 5,500,004 units at a price of $0.30 per unit (each a "Unit").

Each Unit comprised one common share of the Company and one share purchase warrant entitling the holder to acquire one additional common shares of the Company at an exercise price of $0.50 per share until April 28, 2022.

Finder's fees of $63,906.49 were paid to registrants along with the issuance of 213,022 finder's warrants on the same terms as the warrants forming part of the Units.

All of the securities issued in the Placement are subject to resale restrictions expiring on August 29, 2020.

Two directors of the Company participated directly and indirectly in the Placement acquiring an aggregate of 378,850 Units on the same basis as other subscribers. The participation in the placement by insiders of the Company constitutes a "related party transaction" as such term is defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on exemptions from the formal valuation and minority approval requirements under MI 61-101. The Company relied on Section 5.5(a) of MI 61-101 for an exemption from the formal valuation requirement and Section 5.7(1)(a) of MI 61-101 for an exemption from the minority shareholder approval requirement of MI 61-101 as the fair market value of the Placement in so far as the Placement involved interested parties did not exceed 25% of the Company's market capitalization.

Capitalization

Following completion of the Acquisition, the Company now has 63,832,966 issued and outstanding common shares.

The Company also advises that it has extended the terms of 6,914,333 currently existing warrants exercisable at $0.50 per share expiring on dates ranging from March 29, 2020 to August 16, 2020 to April 28, 2021.

Following the completion of the Placement, the Company has an aggregate of 12,627,355 warrants outstanding all exercisable at a price of $0.50 per share.

Changes to Board and Management

Following the completion of the Acquisition, Paul Smith resigned as President, Chief Executive Officer and Chief Financial Officer of the Company and as director.

Patrick Elliott, a founder of the Target has been appointed as the Company's President and CEO and a director and William Fleming has been appointed as the Company's Chief Financial Officer and Corporate Secretary.

The Company's board of directors now comprises, Patrick Elliott, Marc Geen, Matthew McGill and William Fleming.

Update on Proposed Spin-Off of Mining Assets

Pursuant to the arrangement agreement dated June 5, 2018 (the "Arrangement Agreement") between the Company and its wholly owned subsidiary, 1167343 B.C. Ltd. ("Newco"), the Company will complete a plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement") which will result in the transfer of its interests in existing mineral properties along with $1,000,000 in cash, less advances previously made by the Company to Newco of $450,000, in exchange for the issuance of common shares of Newco on the basis of one common shares of Newco for each common share of the Company held. Newco also currently holds the Highfield property, located in Nova Scotia. The Arrangement was approved by the Company's shareholders on August 8, 2019 and received the final approval of the British Columbia Supreme Court on August 12, 2019.

The Company has determined to fix April 28, 2020 as the record date (the "Record Date") for the proposed distribution of Newco shares. The Company will provide a further update on the proposed effective date of the Arrangement and distribution of the Newco shares in a subsequent press release.

Additional Details

Details of the Acquisition and the License are contained in the Company's listing statement dated April 28, 2020 which will be filed on the Company's profile on www.sedar.com and the website of the CSE at www.thecse.com.

Filing of Q4 2019 Financial Statements; Extension for Q1 2020

Further to the Company's press release dated March 30, 2020, the Company is pleased to advise it has now filed its audited annual financial statements and associated management's discussion and analysis ("MD&A") for the year ended November 30, 2019.

The Company has however delayed the release of its interim financial statements and associated MD&A for the three months ended February 29, 2020. The Company will be relying on the 45-day filing and delivery extension for periodic filings required to be made on or before June 1, 2020 as provided by the British Columbia, Alberta and Alberta Ontario Commissions in their recent blanket orders in respect of:

the requirement to file interim financial statements for the three-month period ended February 29, 2020 (the "Interim Financial Statements") within 60 days of the Company's first quarter as required by section 4.4(b) of National Instrument 51-102 ("NI 51-102");
the requirement to file MD& for the period covered by the Interim Financial Statements within 60 days of the Company's first quarter as required by section 5.1(2) of NI 51-102;
the requirement to file certifications of the Interim Financial Statements (the "Interim Certificates" and collectively with the Interim Financial Statements and MD&A, the "Interim Filings") pursuant to section 5.1 of NI 52-109;

The Company expects that the Interim Filings will be filed on or before Friday, May 1, 2020.

There have not been any material business developments since the Company's financial statements and MD&A for the year ended November 30, 2019 other than as disclosed in this press release.

The Company's management and other insiders are subject to a trading black-out that reflects the principles in section 9 of National Policy 11-207 Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions.

ON BEHALF OF PAC ROOTS CANNABIS CORP.

(signed) "Patrick Elliott"
Chief Executive Officer

For further information, please contact:

Pac Roots Cannabis Corp.
www.pacroots.ca
Telephone: 604-609-6171

Not for distribution to United States wire services or dissemination in the United States. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Statements about the Target's future facility expansion plans or Cannabis Act license application are all forward-looking information.

Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include failure to obtain regulatory approval, the continued availability of capital and financing, and general economic, market or business conditions, including the effects of COVID-19. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.

Neither the Canadian Securities Exchange (the "CSE") nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Pac Roots Cannabis Corp.

ReleaseID: 587613

Valeura Energy Inc. Announces Notice of Conference Call

NOTICE OF CONFERENCE CALL

CALGARY, ALBERTA / ACCESSWIRE / April 29, 2020 / Valeura Energy Inc. (TSX:VLE) (LSE:VLU) ("Valeura" or the "Company"), the upstream natural gas company focused on the Thrace Basin of Turkey, will announce its interim unaudited financial statements and operating results for the first quarter of 2020 before markets open on Tuesday, May 12, 2020.

The management team will host an investor and analyst call and question session at 9:00 a.m. Calgary (11:00 a.m Toronto, 4:00 p.m. London) the same day, Tuesday, May 12, 2019. A live audio feed of the call will be available via the webcast link below, and those interested in participating in the question session should use the dial-in numbers below. Please register approximately 15 minutes prior to the start of the call. The quarterly results will be made available on the Company's website at: www.valeuraenergy.com.

Event title: Valeura First Quarter 2020 Results Conference Call
Webcast link: https://produceredition.webcasts.com/starthere.jsp?ei=1312681&tp_key=5a72d7796a
Calgary dial-in: +1 587 880 2171
Toronto dial-in: +1 416 764 8688
North America toll-free: +1 888 390 0546
UK toll-free: +44 0800 6522 435

For further information please contact:

Valeura Energy Inc. (General and Investor Enquiries) +1 403 237 7102
Sean Guest, President and CEO
Heather Campbell, CFO
Robin Martin, Investor Relations Manager
Contact@valeuraenergy.com, IR@valeuraenergy.com

Canaccord Genuity Limited (Joint Corporate Broker) +44 (0) 20 7523 8000
Henry Fitzgerald-O'Connor, James Asensio

CAMARCO (Public Relations, Media Adviser) +44 (0) 20 3757 4980
Owen Roberts, Monique Perks, Hugo Liddy, Billy Clegg
Valeura@camarco.co.uk

Additional information relating to Valeura is also available on SEDAR at www.sedar.com.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, including where such offer would be unlawful. This announcement is not for distribution or release, directly or indirectly, in or into the United States, Ireland, the Republic of South Africa or Japan or any other jurisdiction in which its publication or distribution would be unlawful.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this news release.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Valeura Energy Inc.

ReleaseID: 587614

Legacy ER & Urgent Care Now Offering Federally Approved COVID-19 Antibody Testing

Company warns public to use only antibody tests that have been granted Emergency Use Authorization by the FDA

FRISCO, TX / ACCESSWIRE / April 29, 2020 / Legacy ER & Urgent Care, the national leader in combined emergency-room and urgent-care facilities that operate under one roof, is one of the first in the Dallas-Fort Worth area to offer one of the seven COVID-19 antibody test that has been granted Emergency Use Authorization, also known as EUA by the Federal Drug Administration, also known as FDA. The COVID-19 Antibody test is Abbott test for IgG, also known as Immunoglobulin G – a type of antibody. The test received its EUA authorization on April 26 by the FDA. The COVID-19 antibody determines if an individual has been infected with the disease. COVID-19 antibody testing is available at Legacy ER & Urgent Care's six North Texas locations.

A visit for the COVID-19 antibody test, also known as a coronavirus serological antibody test, at Legacy ER & Urgent Care typically takes no more than 30 minutes to complete. All patients will be screened curbside. Asymptomatic patients will proceed indoors and COVID-19 related symptomatic patients will stay inside their vehicles via temporary curbside service. For patients just wanting the COVID-19 antibody test, 2ml of blood is drawn. The blood is then sent to a partner lab for testing. Results are available within two to five days.

Patients don't need to have — or have had — any COVID-19 symptoms to be tested. Patient responsibility for testing and COVID-19 related visits are covered by many insurance plans. In-Network Insurance Providers are listed at LegacyER.com/Insurance. To determine specific plan coverage for COVID-19 related visits, patients are advised to contact their insurance company for guidance.

"Since the beginning of April, more than 100 antibody tests have shown up in the marketplace that are non-FDA authorized. Many of these COVID-19 tests have turned out not to be accurate nor approved via the FDA's EUA process. Many give patients false positives – meaning that the patient is told that they have COVID-19 antibodies when they actually don't. This is the exact reason why Legacy ER & Urgent Care delayed our antibody testing. The safety of patients is our number one priority. We waited for the FDA to issue an EUA," said Jay Woody, MD, FACEP, chief medical officer of Intuitive Health and a co-founder of Legacy ER & Urgent Care.

"The problem with the hundred or so COVID-19 antibody tests in the market right now is that they are not FDA EUA approved so the validity of the results is questionable," Woody said. "Many of these unapproved tests involve a finger prick with results in 15 minutes. Our test takes two to five days to receive results. While we understand the public's desire to have a test with quick results, we make sure that any COVID-19 tests we provide, we can trust their results."

On Sunday, CNN reported that the FDA said in a statement, "FDA will continue to consider the risks and benefits of our policies as the emergency evolves and adjust as necessary. FDA is constantly evaluating whether our policy needs to change based on new information to protect the public health."

The COVID-19 antibody test is available every day from 7 a.m. to 9 p.m. While no appointments are necessary to receive testing, new patients are encouraged to pre-register online. Each Legacy ER & Urgent Care facility remains open, safe and clean for all patients. To answer additional questions about Legacy ER & Urgent Care's procedures regarding COVID-19, visit them online.

ABOUT LEGACY ER & URGENT CARE
Legacy ER & Urgent Care is a combined emergency room and urgent-care center under one roof. The patient-centered retail-care model is built on a proven business system focused on concierge-level customer service and transparency. Each location has on-site lab equipment, a radiology suite with X-ray and multislice CT scanners and is open 24 hours a day, seven days a week. Every patient is seen by an ER-trained physician. Patients only pay for the care they need, as objective criteria determine whether emergency or urgent care is required. This proven model establishes a cost-effective, personal and time-efficient way to deliver high-quality medical services at the appropriate cost, garnering long-term patient loyalty. Legacy ER & Urgent Care currently operates six locations in North Texas, in Allen, Coppell, East Frisco, West Frisco, McKinney and North Richland Hills. Legacy ER & Urgent Care is an Intuitive Health company. For more information, visit LegacyER.com, follow the company's blog, or follow them on social media on Facebook and Instagram.

Media Contact:
Jo Trizila, TrizCom PR
Office: 972-247-1369
Cell/Text: 214-232-0078
Email: Jo@TrizCom.com

SOURCE: Legacy ER & Urgent Care

ReleaseID: 587609

Range XTD: The Best Way to Kill Dead WIFI Zones

HONG KONG / ACCESSWIRE / April 29, 2020 / Today we all know about the pandemic situation around the world which has led all the employees to work from their homes. Not only this situation, but some organizations also have a certain number of days fixed in a month when an employee can sit in their comfort zone and work, and as we know freelancers work from their respective homes. This phenomenon is called Work from home which is designed for the employees to have their comfort zone and give efficient productivity but most of them fail due to the dropping off the Internet. This continuous issue always comes in front as a hurdle between a hardworking employee and his productivity. This happens because your place of work is a WIFI dead spot.

As it is truly said, "solution to a problem brings the best business Idea". Keeping this in mind RangeXTD was found.

RangeXTD is a lifesaver device designed to extend the coverage of all WAN networks. In simple words, this device helps you get rid of all the WIFI dead spots and offers wireless speed up to 300mbps. This device is also known as WIFI booster for not just being an extender to the router but also increasing the speed of it. The best part about it is that the increased speed of the internet is all Free which means you do not have to pay a penny more for any kind of data transfers.

This Device needs to be connected with the Router and WIFI network while it is electrically joined with a socket.

Double internal 3D antennas on it are utilized to broaden your signal, and cooling vents at the edges doesn't let the gadget to overheat. We additionally have LAN ports on the gadget.

On the facade of the gadget, there's a Wireless association status bar, so you can generally observe the status of your association. A straightforward sliding catch permits you to switch modes, and WPS makes sure about your association. It has some connection modes such as WiFi repeater, Access point, and Router.

We nearly neglected to discuss that it is so natural to set this thing up. It takes under two minutes to get your RangeXTD ready for action.

Start by connecting this gadget in the stay with the most fragile sign. Adhere to the included directions, and you're all set. The EZ arrangement wizard truly makes it so natural to get your RangeXTD associated with your system and broadening its sign.

RangeXTD works and it works Effectively.
In case you're similar to us, you're distrustful of everything. What's more, you ought to be incredulous. Everybody is attempting to make a speedy buck selling items that don't generally work, particularly nowadays.

The working of RangeXTD looks simple. It stretches out your WiFi sign to give you a solid association in each room of the house.

Individuals are stating they're at last ready to work in their front room "office" subsequent to introducing RangeXTD, and best of all they have never lost association during their Zoom gatherings any longer. Their association was solid and stable. You will have the option to stream recordings without buffering or losing HD quality.

Media Details
Company: RangeXTD
Email: support@buyrangextd.com
Website: https://buyrangextd.com

SOURCE: RangeXTD

ReleaseID: 587611

CLASS ACTION UPDATE for NCLH, FITB and BBBY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / April 29, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

NCLH Shareholders Click Here: https://www.zlk.com/pslra-1/norwegian-cruise-line-holdings-ltd-loss-form?prid=6254&wire=1
FITB Shareholders Click Here: https://www.zlk.com/pslra-1/fifth-third-bancorp-loss-form?prid=6254&wire=1
BBBY Shareholders Click Here: https://www.zlk.com/pslra-1/bed-bath-beyond-inc-loss-form?prid=6254&wire=1

* ADDITIONAL INFORMATION BELOW *

Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH)

NCLH Lawsuit on behalf of: investors who purchased February 20, 2020 – March 12, 2020
Lead Plaintiff Deadline : May 11, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/norwegian-cruise-line-holdings-ltd-loss-form?prid=6254&wire=1

According to the filed complaint, during the class period, Norwegian Cruise Line Holdings Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was employing sales tactics of providing customers with unproven and/or blatantly false statements about COVID-19 to entice customers to purchase cruises, thus endangering the lives of both their customers and crew members; and (2) as a result, Defendants' statements regarding the Company's business and operations were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Fifth Third Bancorp (NASDAQ:FITB)

FITB Lawsuit on behalf of: investors who purchased February 26, 2016 – March 6, 2020
Lead Plaintiff Deadline : June 8, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fifth-third-bancorp-loss-form?prid=6254&wire=1

According to the filed complaint, during the class period, Fifth Third Bancorp made materially false and/or misleading statements and/or failed to disclose that: (i) as a result of Fifth Third Bank's aggressive incentive policies to promote its cross-sell strategy, Fifth Third Bank employees engaged in unauthorized conduct with customer accounts; (ii) since at least 2008, Fifth Third Bank, and by extension, Fifth Third, was aware of such unauthorized conduct and, thus, that it was violating relevant regulations and laws aimed at protecting its consumers; (iii) Fifth Third failed to properly implement and monitor its cross-sell program, detect and stop misconduct, and identify and remediate harmed consumers; (iv) all the foregoing subjected the Company to a foreseeable risk of heightened regulatory scrutiny or investigation; (v) Fifth Third's revenues were in part the product of unlawful conduct and thus unsustainable; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Bed Bath & Beyond Inc. (NASDAQ:BBBY)

BBBY Lawsuit on behalf of: investors who purchased October 2, 2019 – February 11, 2020
Lead Plaintiff Deadline : June 15, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/bed-bath-beyond-inc-loss-form?prid=6254&wire=1

According to the filed complaint, during the class period, Bed Bath & Beyond Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) due to "aggressive disposition of inventory," the Company lacked sufficient inventory in key categories to support holiday sales; (2) the Company's internal control over inventory levels and financial reporting was not effective; (3) as a result of the foregoing, the Company was likely to experience reduced sales; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 587603

Clean Coal Technologies (CCTC) Announces Upcoming Annual Shareholder Webcast

Annual Shareholder meeting to be Webcast on April 30, 2020 due to Coronavirus

NEW YORK, NY / ACCESSWIRE / April 29, 2020 / Clean Coal Technologies, Inc., (OTCQB:CCTC) ("CCTI" or the "Company"), the leading clean-energy company utilizing patented and proven technology to convert run of mine coal into a cleaner burning and more efficient stabilized fuel, today announced that the company's annual Shareholder Meeting will be held online and tape-delayed due to the current coronavirus pandemic. Shareholders are encouraged to submit questions for management to address via email before the Thursday 7.00am ET deadline.

"We are very sorry that we will not be able to host our annual Shareholder Meeting under normal circumstances and in-person," stated Sean Mahoney, spokesperson for CCTI. "Due to the current pandemic, most companies are being forced to operate in this way in order to maintain social distancing and avoid any person-to-person transmission of the virus. Therefore we are encouraging shareholders to submit questions that management can address via our tape-delayed webcast."

The Annual shareholder Meeting for Clean Coal Technologies, Inc will take place via web-cast on April 30, 2020 at 10:00am ET. For log-in information please use this link:

https://zoom.us/j/91551686239

For shareholder questions, please submit them to: aneary@cleancoaltechnologiesinc.com

About Clean Coal Technologies, Inc.

Clean Coal Technologies, Inc., a cleaner-energy technology company with headquarters in New York City, NY, holds patented process technology and other intellectual property that converts raw coal into a cleaner burning fuel. The Company's trademarked end products, "Pristine" coals, are significantly more efficient, less polluting, more cost-effective, and provide more heat than untreated coal. The principal elements of the Company's pre-combustion technology are based on well-proven science and tried-and-tested industrial components. The Company's clean coal technology may reduce some 90% of chemical pollutants from coal, including Sulfur and Mercury, thereby resolving emissions issues affecting coal-fired power plants. For more information about Clean Coal Technologies please visit: www.cleancoaltechnologiesinc.com.

Forward Looking Statements

This release may include forward-looking statements related to CCTI's plans, beliefs and goals, which involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such statements include, but are not limited to, statements about CCTI's plans, objectives, expectations and intentions with respect to future operations, its products, its ability to secure financing for its operations, the impact on the industry and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," and other words of similar meaning or the use of future dates. Additional details about CCTI's business and its operations that could affect CCTI's actual results are described in CCTI's filings with the Securities and Exchange Commission, including the "Risk Factors" that are part of its most recent annual report on Form 10-K for the year ended December 31, 2019 and in each of its subsequently filed periodic reports. All forward-looking statements in this release speak only as of the date of this news release. CCTI undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For More information please contact:

Sean Mahoney, Media consultant:
smahoney@cleancoaltechnologiesinc.com

SOURCE: Clean Coal Technologies, Inc.

ReleaseID: 587604

Zinc8 Energy Solutions Announces Delay in Filing Under CSA Instrument Governing Relief Under COVID-19

VANCOUVER, BC / ACCESSWIRE / April 29, 2020 / Zinc8 Energy Solutions Inc. (CSE:ZAIR) (the "Company") announces that due to circumstances created by the COVID-19 pandemic, the British Columbia Securities Commission and other members of the Canadian Securities Administrators granted issuers in the Canadian securities industry up to an additional 45 days to complete year-end statutory filings.

Due to delays associated with COVID-19, the Company does not believe that it will be able to file its December 31, 2019 audited annual financial statements by its usual 120-day deadline of April 29, 2020 and will be relying on the extension. Management anticipates the Company will file its annual financial statements and Management Discussion and Analysis on or before June 13, 2020.

As required by the conditions of the extension, the Company's management and other insiders will be subject to a trading black-out that reflects the principles in Section 9 of National Policy 11-207 until its financial statements are filed.

All material business developments since the filing of the Company's interim financial statements and associated management's discussion and analysis, for the interim period ending September 30, 2019, have been disclosed by the Company by way of news release. Please view the company's SEDAR profile at www.sedar.com for further information.

About Zinc8 Energy Solutions

Zinc8 has assembled an experienced team to execute the development and commercialization of a dependable low-cost zinc-air battery. This mass storage system offers both environmental and efficiency benefits. Zinc8 strives to meet the growing need for secure and reliable power.

To watch a short video outlining Zinc8's technology, please visit:

https://zinc8energy.com

More about the Zinc8 Energy Storage System (ESS)

The Zinc8 ESS is a modular Energy Storage System designed to deliver power in the range 20kW – 50MW with capacity of 8 hours of storage duration or higher. With the advantage of rechargeable zinc-air flow battery technology, the system can be configured to support a wide range of long-duration applications for microgrids and utilities. Since the energy storage capacity of the system is determined only by the size of the zinc storage tank, a very cost-effective and scalable solution now exists as an alternative to the fixed power/energy ratio of the lithium ion battery.

Technology

The Zinc8 ESS is based upon unique patented zinc-air battery technology. Energy is stored in the form of zinc particles, similar in size to grains of sand. When the system is delivering power, the zinc particles are combined with oxygen drawn from the surrounding air. When the system is recharging, zinc particles are regenerated, and oxygen is returned to the surrounding air.

Applications

The flexibility of the Zinc8 ESS enables it to service a wide range of applications. Typical examples include:

Smoothing energy derived from renewable sources such as wind and solar
Commercial/Industrial backup replacing diesel generators
Industrial and grid scale, on-demand power for peak shaving and standby reserves
Grid-scale services such as alleviating grid congestion, deferring transmission/distribution upgrades, energy trading and arbitrage, and increasing renewable energy penetration.

Architecture

The Zinc8 ESS is designed according to a modular architecture that enables a wide variety of system configurations to be created from a small number of common subsystems. Each subsystem implements a single element of the technology:

The Zinc Regeneration Subsystem (ZRS) provides the recharging function
The Fuel Storage Subsystem (FSS) provides the energy storage function
The Power Generation Subsystem (PGS) provides the discharging function

Contact Information

Patrick Butler
Corporate Development
Telephone: 1.604.681.1568
patrick@zinc8energy.com
Web: investors@zinc8energy.com

SOURCE: Zinc8 Energy Solutions Inc.

ReleaseID: 587600

MMJ International Holdings Wins IRB Approval For Marijuana Study In Huntington’s Disease

ST. PETERSBURG, FL / ACCESSWIRE / April 29, 2020 / MMJ International Holdings, the premier medical cannabis research company, announced that it has received conditional approval from the Institutional Review Board for its FDA Huntington's Disease study.

What is an IRB and why is this significant?

Under FDA regulations, an IRB is an independent group of professionals that has been formally designated to review and monitor biomedical research involving human subjects. In accordance with FDA regulations, an IRB has the authority to approve required protocols and monitor the clinical trial to protect the rights and welfare of human subjects involved in research activities being conducted by MMJ.

MMJ's CEO, Duane Boise stated, ″MMJ's IRB conditional approval is a significant accomplishment as it establishes credibility to MMJ's scientific approach to marijuana drug development. We continue to set industry standards by following FDA and DEA guidance in our development of plant-derived cannabinoid therapeutics."

Dr. Elio Mariani, MMJ International Holdings director of drug development and experienced pharmaceutical veteran stated that "We firmly believe that our MMJ natural whole plant derived molecules with a unique combination of pharmacological properties will be FDA approved as a safe and effective prescription drug that can be of great benefit in treating patients with MS and HD diseases,"

MMJ International Holdings has several academic institutions preparing to study cannabis in Multiple Sclerosis and Huntington's disease. The MMJ clinical trials will provide the necessary data to the FDA to prove that cannabis can treat essential tremors, a neurological disorder that causes involuntary shaking.

Eager to initiate its FDA clinical trials, MMJ International Holdings recently made history by being the first cannabis company to import highly concentrated medical marijuana extracts into the United States for clinical trial use. Health Canada and the US Drug Enforcement Agency approved MMJ to ship the compounds for its clinical trials.

For continued quality supply of its marijuana plant products, MMJ International Holdings has negotiated a deal with MMJ BioPharma Cultivation,Inc who has applied for the much coveted DEA federal marijuana growers license. Under the terms of the deal, MMJ BioPharma Cultivation will be supplying pharmaceutical grade marijuana for MMJ International Holdings for its future pharmaceutical drug development needs.

Tim Moynahan the company's chair stated "We are pleased with the DEA 's cooperation and support to facilitate our company's scientific mission to develop these medications to provide relief to patients suffering from these chronic diseases."

Contact:

Michael Sharp
561-627-9455

SOURCE: MMJ International Holdings

ReleaseID: 587594